Kiniksa Pharmaceuticals International (KNSA) Free Cash Flow (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Free Cash Flow for 10 years, with the latest figure at $50.1 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 124.72% year-over-year to $50.1 million; the trailing twelve-month figure through Mar 2026 stood at $165.7 million (up 277.1% YoY), and the FY2025 full-year result was $137.9 million, up 440.03% from the prior year.
• Free Cash Flow for Q1 2026 stood at $50.1 million, down from $54.7 million in the prior quarter.
• The five-year high for Free Cash Flow was $62.0 million in Q3 2022, with the low at -$36.8 million in Q1 2022.
• Historically, Free Cash Flow has averaged $13.7 million across 5 years, with a median of $5.2 million in 2024.
• Annual changes were most pronounced in 2024 — Free Cash Flow slumped 113.18% — and 2025, when it jumped 1579.43%.
• Kiniksa Pharmaceuticals International's Free Cash Flow stood at -$11.5 million in 2022, then surged by 136.98% to $4.3 million in 2023, then jumped by 338.07% to $18.7 million in 2024, then surged by 192.74% to $54.7 million in 2025, then declined by 8.5% to $50.1 million in 2026.
• The last three Free Cash Flow figures came in at $50.1 million (Q1 2026), $54.7 million (Q4 2025), and $33.1 million (Q3 2025), per Business Quant data.